Otsuka Holdings

At the annual general meeting on 27 March 2026, Otsuka approved a dividend of 140.00 JPY for 2025, an increase of 16.67% year-on-year, bringing total distributions to 70.98 billion JPY (total payout +6.31% year-on-year). The stock traded at 11,400 JPY on the AGM day and will trade ex-dividend on 30 March 2026; the dividend yield for 2025 is 1.58% (previous year 1.40%). FactSet expects a 2026 dividend of 142.73 JPY (estimated yield 1.25%). Otsuka has a market capitalization of 6.012 trillion JPY, a P/E ratio of 12.95, 2025 revenue of 2.469 trillion JPY and EPS of 685.06 JPY. » Mere på finanzen.net

The US FDA has accepted Otsuka’s application for Centanafadin for priority review and set the PDUFA decision date for July 24, 2026. Centanafadin is a once-daily norepinephrine-, dopamine- and serotonin-reuptake inhibitor (NDSRI) for the treatment of ADHD in children, adolescents and adults. The submission is supported by four phase-3 studies that showed significant improvements versus placebo. Common adverse events included decreased appetite, nausea, rash, fatigue and, in adults, headache. » Mere på de.investing.com

4D Molecular Therapeutics has agreed a strategic partnership with Otsuka to develop and commercialize 4D‑150 for wet AMD and DME in Japan, China, Australia and other APAC markets. 4DMT will receive an $85 million upfront payment, at least $50 million in cost sharing over the next three years, up to $336 million in milestone payments and tiered high‑single‑digit royalties; Otsuka obtains exclusive rights in APAC while 4DMT retains rights in the US, Latin America and Europe and will lead global Phase‑3 activities. The deal bolsters funding amid high cash burn (negative EBITDA of $215.82 million) and follows positive Phase‑2/3 (SPECTRA) data showing a significant reduction in treatment frequency; Goldman Sachs and RBC reaffirm positive views with price targets of $38 and $26 respectively. FDMT stock is trading near its 52‑week high after a 235% rise in six months. » Mere på de.investing.com

Cantargia AB said in its Q2 earnings call that it struck a $630 million deal with Otsuka, including a $33 million upfront payment, and announced a 10% reduction in operating costs. The stock fell about 4.3% after the call as investors await the expected revenue recognition from the deal in Q3 2025. The FDA granted Nadinolumab fast-track status for pancreatic cancer; risks remain around the milestone timing and clinical trial results. » Mere på de.investing.com